By Thamanna Hussain
Our firm's Incretin pancreatic cancer cases may become part of a proposed motion for consolidation in San Diego, California. These cases allege numerous causes of action relating to a defective class of drugs, referred to as the incretin mimetic class, which includes Byetta, Januvia, Janumet, and Victoza. Incretin drugs basically mimic the incretin hormones that our body uses to stimulate the production of insulin and are used to lower blood sugar levels in patients with type 2 diabetes. Earlier this month, the FDA announced that it is investigating a potential connection between pancreatic cancer and Incretin mimetic products. Studies show a significant increase in cancer cases, including pre-cancerous cellular growth abnormalities which were 50% larger than normal.
Plaintiffs accuse the manufacturers of failure to warn, designing defective drugs, negligence, breach of warranty, negligent misrepresentation, and fraudulent concealment and seek compensation for injuries, medical expenses, pain, suffering and other economic damages, as well as punitive damages. Currently, there are 53 substantially similar actions pending in 7 different judicial districts in the country alleging similar wrongful conduct. We concur with the consolidated proceedings before the Honorable Judge Anthony J. Battaglia and eagerly look forward to the litigation.